Cross‐Cohort Gut Microbiome Signatures of Irritable Bowel Syndrome Presentation and Treatment
Advanced Science · 2024-11 · 11 (41)
DOI: 10.1002/advs.202308313 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 07.09.2024. Verfasst von Junhui Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: APC Microbiome Ireland, University College Cork, Cork, T12 K8AF, Ireland. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Irritable Bowel Syndrome. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Centre award from Science Foundation Ireland to APC Microbiome Ireland, Enterprise Ireland award.
Abstract (Originalsprache)
Irritable bowel syndrome (IBS) is a prevalent disorder of gut‐brain interaction without a reliable cure. Evidence suggests that an alteration of the gut microbiome may contribute to IBS pathogenesis, motivating the development of microbiome‐targeted therapies to alleviate IBS symptoms. However, IBS‐specific microbiome signatures are variable across cohorts. A total of 9204 datasets were meta‐analyzed, derived from fourteen IBS microbiome discovery cohorts, three validation cohorts for diet‐microbiome interactions, and five rifaximin therapy cohorts. The consistent bacterial species and functional signatures associated with IBS were identified. Network analysis revealed two distinct IBS‐enriched microbiota clusters; obligate anaerobes that are found commonly in the gut, and facultative anaerobes typically present in the mouth, implying a possible association between oral bacterial translocation to gut and IBS pathogenesis. By analyzing diet‐microbiome interactions, microbiota‐targeted diets that can potentially modulate the altered gut microbiota of IBS subjects toward a healthy status were identified. Furthermore, rifaximin treatment of IBS subjects was linked with a reduction in the abundance of facultatively anaerobic pathobionts. Gut microbiome signatures were identified across IBS cohorts that may inform the development of therapies for microbiome modulation in IBS. The microbiota‐targeted diet patterns described may enable nutritional intervention trials in IBS and for assisting dietary management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- APC Microbiome Ireland, University College Cork, Cork, T12 K8AF, Ireland.
- School of Microbiology, University College Cork, Cork, T12 K8AF, Ireland.
- School of Food and Nutritional Sciences, University College Cork, Cork, T12 K8AF, Ireland.
- Department of Medicine, University College Cork, Cork, T12 K8AF, Ireland.
ORCID-Profile: Junhui Li, Tarini Shankar Ghosh, Elke Arendt, Fergus Shanahan, Paul W O'Toole
Förderung
- Centre award from Science Foundation Ireland to APC Microbiome Ireland
- Enterprise Ireland award
Zitieren
APA
Li, J., Ghosh, T. S., Arendt, E., Shanahan, F., & O'Toole, P. W. (2024). Cross‐Cohort Gut Microbiome Signatures of Irritable Bowel Syndrome Presentation and Treatment. Advanced Science, 11(41). https://doi.org/10.1002/advs.202308313
Vancouver
Li J, Ghosh TS, Arendt E, Shanahan F, O'Toole PW. Cross‐Cohort Gut Microbiome Signatures of Irritable Bowel Syndrome Presentation and Treatment. Advanced Science. 2024;11(41). doi:10.1002/advs.202308313
BibTeX
@article{Li2024,
author = {Li, Junhui and Ghosh, Tarini Shankar and Arendt, Elke and Shanahan, Fergus and O'Toole, Paul W},
title = {Cross‐Cohort Gut Microbiome Signatures of Irritable Bowel Syndrome Presentation and Treatment},
journal = {Advanced Science},
year = {2024},
volume = {11},
number = {41},
doi = {10.1002/advs.202308313}
}
EUVIMED